Influences of Long-Term, High-Dose Acetaminophen Administration on Liver Function Markers in Healthy Japanese Adults

Ildae Song, R. Tanaka, Masako Aso, Yasutoshi Sakamoto, M. Maeda, Michiru Ochiai, Yoshiro Saito, K. Maekawa, Y. Kumagai
{"title":"Influences of Long-Term, High-Dose Acetaminophen Administration on Liver Function Markers in Healthy Japanese Adults","authors":"Ildae Song, R. Tanaka, Masako Aso, Yasutoshi Sakamoto, M. Maeda, Michiru Ochiai, Yoshiro Saito, K. Maekawa, Y. Kumagai","doi":"10.3999/JSCPT.48.153","DOIUrl":null,"url":null,"abstract":"Background : Acetaminophen is widely used as an analgesic and antipyretic; however, acetaminophen overdose is known to cause hepatic injury. However, minor and self-limiting alanine aminotransferase ( ALT ) elevation unrelated to hepatic injury is occasionally observed in individuals receiving high-dose acetaminophen. The aim of this study was to evaluate the changes in liver function markers induced by long-term, high-dose acetaminophen administration. Methods : Acetaminophen ( 3000 mg / day ) or placebo was re-peatedly administered to 242 healthy Japanese adults for 28 days. Plasma samples collected on Day 1 were used to measure the pharmacokinetics of acetaminophen. Liver function was monitored in terms of aspartate aminotransferase ( AST ) , ALT, alkaline phosphatase ( ALP ) , total bilirubin ( T-Bil ) , and high mobility group box 1 ( HMGB-1 ) levels for 35 days, from the day of the first dose. Subjects were withdrawn from the study if their AST, ALT, or ALP levels exceeded twice the respective upper limit of normal ( 2 × ULN ) . Results : From a total of 242 subjects, 202 and 40 subjects were assigned to the acetaminophen group and the placebo group, respectively. Twelve subjects in the acetaminophen group ( 6 . 0 %) were withdrawn owing to ALT elevation over 2 × ULN; no subjects were withdrawn from the placebo group. During the study period, ALT was higher in the acetaminophen group than in the placebo group, and increased from Day 7 to 14 after the start of administration. However, no evidence of hepatic injury owing to acetaminophen was observed, and the ALT elevation was attenuated after Day 14. Moreover, no correlation was observed between maximum ALT and levels of HMGB-1, a novel biomarker candidate for hepatic injury, during the study period. These findings led us to conclude that the ALT elevation was not caused by hepatic injury. Conclusion : ALT elevation > 2 × ULN was observed in 6 . 0 % of subjects in the acetaminophen group. However, no subjects developed hepatic injury, and ALT levels started to return to the normal values even during continued administration. The phenomenon of adaptation may be involved in these changes. -","PeriodicalId":21491,"journal":{"name":"Rinsho Yakuri\\/japanese Journal of Clinical Pharmacology and Therapeutics","volume":"86 1","pages":"153-159"},"PeriodicalIF":0.0000,"publicationDate":"2017-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rinsho Yakuri\\/japanese Journal of Clinical Pharmacology and Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3999/JSCPT.48.153","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background : Acetaminophen is widely used as an analgesic and antipyretic; however, acetaminophen overdose is known to cause hepatic injury. However, minor and self-limiting alanine aminotransferase ( ALT ) elevation unrelated to hepatic injury is occasionally observed in individuals receiving high-dose acetaminophen. The aim of this study was to evaluate the changes in liver function markers induced by long-term, high-dose acetaminophen administration. Methods : Acetaminophen ( 3000 mg / day ) or placebo was re-peatedly administered to 242 healthy Japanese adults for 28 days. Plasma samples collected on Day 1 were used to measure the pharmacokinetics of acetaminophen. Liver function was monitored in terms of aspartate aminotransferase ( AST ) , ALT, alkaline phosphatase ( ALP ) , total bilirubin ( T-Bil ) , and high mobility group box 1 ( HMGB-1 ) levels for 35 days, from the day of the first dose. Subjects were withdrawn from the study if their AST, ALT, or ALP levels exceeded twice the respective upper limit of normal ( 2 × ULN ) . Results : From a total of 242 subjects, 202 and 40 subjects were assigned to the acetaminophen group and the placebo group, respectively. Twelve subjects in the acetaminophen group ( 6 . 0 %) were withdrawn owing to ALT elevation over 2 × ULN; no subjects were withdrawn from the placebo group. During the study period, ALT was higher in the acetaminophen group than in the placebo group, and increased from Day 7 to 14 after the start of administration. However, no evidence of hepatic injury owing to acetaminophen was observed, and the ALT elevation was attenuated after Day 14. Moreover, no correlation was observed between maximum ALT and levels of HMGB-1, a novel biomarker candidate for hepatic injury, during the study period. These findings led us to conclude that the ALT elevation was not caused by hepatic injury. Conclusion : ALT elevation > 2 × ULN was observed in 6 . 0 % of subjects in the acetaminophen group. However, no subjects developed hepatic injury, and ALT levels started to return to the normal values even during continued administration. The phenomenon of adaptation may be involved in these changes. -
长期大剂量对乙酰氨基酚对日本健康成人肝功能指标的影响
背景:对乙酰氨基酚是一种广泛使用的镇痛解热药;然而,已知对乙酰氨基酚过量会引起肝损伤。然而,偶尔在服用大剂量对乙酰氨基酚的个体中观察到与肝损伤无关的轻度和自限性谷丙转氨酶(ALT)升高。本研究的目的是评估长期大剂量对乙酰氨基酚引起的肝功能指标的变化。方法:对乙酰氨基酚(3000 mg / d)或安慰剂对242名日本健康成人重复给予28天。第1天采集血浆样品,测定对乙酰氨基酚的药代动力学。从第一次给药之日起,监测35天的肝功能,包括天冬氨酸转氨酶(AST)、ALT、碱性磷酸酶(ALP)、总胆红素(T-Bil)和高迁移率组盒1 (HMGB-1)水平。如果AST、ALT或ALP水平超过各自正常上限(2 × ULN)的两倍,则受试者退出研究。结果:242例受试者中,对乙酰氨基酚组202例,安慰剂组40例。对乙酰氨基酚组12例(6;0%)由于ALT升高超过2倍ULN而被撤回;没有受试者退出安慰剂组。在研究期间,对乙酰氨基酚组ALT高于安慰剂组,并且在给药后第7天至第14天ALT升高。然而,没有观察到对乙酰氨基酚引起肝损伤的证据,并且在第14天ALT升高减弱。此外,在研究期间,最大ALT与HMGB-1(一种新的肝损伤候选生物标志物)水平之间没有相关性。这些结果使我们得出结论,ALT升高不是由肝损伤引起的。结论:6例患者ALT升高> 2 × ULN。对乙酰氨基酚组0%的受试者。然而,没有受试者发生肝损伤,即使在继续给药期间,ALT水平也开始恢复到正常值。这些变化可能与适应现象有关。-
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信